Abstract
Dysregulation of long non-coding RNA zinc finger antisense 1 (ZFAS1) has been reported in many types of cancers. We performed a synthetic analysis to clarify its prognostic significance as a cancer molecular-marker. Several databases (including PubMed, Web of Science, Embase together with Wanfang and China National Knowledge Internet database) were retrieved to identify ZFAS1-related articles. A total of eight articles were included in this meta-analysis. Hazard ratios (HR) and 95% confidence intervals (CI) were applied to assess the association between ZFAS1 expression level and overall survival (OS). Odds ratios (OR) were calculated with RevMan 5.3 software to determine the relationship between ZFAS1 expression and clinicopathologic features. The pooled results of the meta-analysis indicated that high ZFAS1 expression level was positively correlated with poor OS (HR = 1.87, 95% CI: 1.38-2.36, p< 0.001) in human solid cancers. The statistical significance was also observed in subgroup analysis stratified by the cancer type, analysis method, sample size and follow-up time. Furthermore, the elevated ZFAS1 expression was significantly related to positive lymph node metastasis (OR = 4.18, 95% CI: 2.70-6.48, p< 0.001). The present results suggest that ZFAS1 might be served as a novel promising biomarker for prognosis in Chinese patients with solid cancers.
Highlights
Cancer is a leading cause of mortality worldwide with 14.1 million newly diagnosed cases and 8.2 million deaths each year [1, 2]
The pooled results of the meta-analysis indicated that high zinc finger antisense 1 (ZFAS1) expression level was positively correlated with poor overall survival (OS) (HR = 1.87, 95% confidence intervals (CI): 1.38-2.36, p< 0.001) in human solid cancers
A total of 6 different types of cancer were included in present analysis, with 2 colorectal cancer, 2 gastric cancer, 1 hepatocellular carcinoma, 1 non-small cell lung cancer, 1 epithelial ovarian cancer and 1 glioma
Summary
Cancer is a leading cause of mortality worldwide with 14.1 million newly diagnosed cases and 8.2 million deaths each year [1, 2]. Albeit some dramatic therapeutic advances have been developed, survival rate in 5 years was still poor for the majority of cancer patients since malignant progression [2]. Novel biomarkers for predicting clinical prognosis are critical and necessary for prognostic accuracy and therapeutic decision-making. Long noncoding RNA (lncRNA) are mRNA-like transcripts with more than 200 nucleotides in length and incapable of protein synthesis [3]. It was considered as the “noise” of transcriptions, nowadays it has attracted great attentions for its major regulatory roles in diverse biological processes and diseases [4,5]. Dysregulation of lncRNAs has been reported in cancers and it was correlated with evolution, progression and prognosis in many kinds of cancers, they appear to be potential new prognostic biomarkers in cancers [6,7]
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
